KR20170048541A - 스미스 마제니스 증후군을 치료하기 위한 타시멜테온 - Google Patents

스미스 마제니스 증후군을 치료하기 위한 타시멜테온 Download PDF

Info

Publication number
KR20170048541A
KR20170048541A KR1020177009052A KR20177009052A KR20170048541A KR 20170048541 A KR20170048541 A KR 20170048541A KR 1020177009052 A KR1020177009052 A KR 1020177009052A KR 20177009052 A KR20177009052 A KR 20177009052A KR 20170048541 A KR20170048541 A KR 20170048541A
Authority
KR
South Korea
Prior art keywords
individual
melatonin
sleep
administered
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177009052A
Other languages
English (en)
Korean (ko)
Inventor
크리스챤 레이브단
미하엘 에이치. 폴리메로폴로스
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54147267&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20170048541(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020247002426A priority Critical patent/KR20240015729A/ko
Publication of KR20170048541A publication Critical patent/KR20170048541A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y10S514/923—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Electric Connection Of Electric Components To Printed Circuits (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Processing Of Solid Wastes (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Led Device Packages (AREA)
  • Saccharide Compounds (AREA)
  • Coils Or Transformers For Communication (AREA)
  • Indole Compounds (AREA)
KR1020177009052A 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온 Ceased KR20170048541A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247002426A KR20240015729A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462044856P 2014-09-02 2014-09-02
US62/044,856 2014-09-02
US201562169635P 2015-06-02 2015-06-02
US62/169,635 2015-06-02
PCT/US2015/047610 WO2016036619A1 (en) 2014-09-02 2015-08-29 Tasimelteon for treating smith-magenis syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247002426A Division KR20240015729A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Publications (1)

Publication Number Publication Date
KR20170048541A true KR20170048541A (ko) 2017-05-08

Family

ID=54147267

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177009052A Ceased KR20170048541A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온
KR1020247002426A Pending KR20240015729A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247002426A Pending KR20240015729A (ko) 2014-09-02 2015-08-29 스미스 마제니스 증후군을 치료하기 위한 타시멜테온

Country Status (17)

Country Link
US (5) US10179119B2 (enExample)
EP (2) EP3188727B1 (enExample)
JP (3) JP6903571B2 (enExample)
KR (2) KR20170048541A (enExample)
CN (2) CN106604726A (enExample)
AU (2) AU2015312252B2 (enExample)
BR (1) BR112017003644A2 (enExample)
CA (2) CA3124872A1 (enExample)
DK (1) DK3188727T3 (enExample)
ES (1) ES2936833T3 (enExample)
FI (1) FI3188727T3 (enExample)
HR (1) HRP20230070T1 (enExample)
HU (1) HUE061051T2 (enExample)
MX (1) MX386150B (enExample)
PT (1) PT3188727T (enExample)
SI (1) SI3188727T1 (enExample)
WO (1) WO2016036619A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
CN106604726A (zh) * 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
EP3761974A1 (en) * 2018-03-04 2021-01-13 Vanda Pharmaceuticals Inc. Treatment of disorders with tasimelteon
JP2022500420A (ja) * 2018-09-12 2022-01-04 バンダ・ファーマシューティカルズ・インコーポレイテッドVanda Pharmaceuticals Inc. 睡眠又は睡眠後パフォーマンスの改善
NZ811397A (en) 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof
US20230314471A1 (en) 2020-08-27 2023-10-05 Yokowo Co., Ltd. Inspection device
AU2022345260A1 (en) * 2021-09-14 2024-04-04 Vanda Pharmaceuticals Inc. Treatment of sleep disturbances in autism spectrum disorder patients

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100499106B1 (ko) 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US20050137247A1 (en) 2003-12-22 2005-06-23 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of hypertension
US7754902B2 (en) 2006-05-18 2010-07-13 Vanda Pharmaceuticals, Inc. Ruthenium(II) catalysts for use in stereoselective cyclopropanations
KR101587394B1 (ko) 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
US20080260837A1 (en) 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
KR100928515B1 (ko) 2008-04-02 2009-11-26 주식회사 동부하이텍 데이터 수신 장치
WO2011009102A1 (en) 2009-07-16 2011-01-20 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
IL330095A (en) * 2012-01-26 2026-08-01 Vanda Pharmaceuticals Inc Tesimalta for use in the treatment of asynchronous circadian rhythm of cortisol
CN102675268A (zh) * 2012-05-18 2012-09-19 济南志合医药科技有限公司 制备（1r，2r）-2-（2,3-二氢苯并呋喃-4-基）环丙甲胺的方法
US10376487B2 (en) * 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
CN106604726A (zh) 2014-09-02 2017-04-26 万达制药公司 用于治疗史密斯‑马吉利综合征的他司美琼
NZ811397A (en) * 2019-12-13 2025-11-28 Vanda Pharmaceuticals Inc Liquid tasimelteon formulations and methods of use thereof

Also Published As

Publication number Publication date
JP7252390B2 (ja) 2023-04-04
US20190105297A1 (en) 2019-04-11
EP4137129A1 (en) 2023-02-22
ES2936833T3 (es) 2023-03-22
EP3188727B1 (en) 2022-11-09
US20170239210A1 (en) 2017-08-24
JP2022078291A (ja) 2022-05-24
SI3188727T1 (sl) 2023-03-31
NZ729901A (en) 2020-09-25
CN116098887A (zh) 2023-05-12
JP6903571B2 (ja) 2021-07-14
AU2020239640A1 (en) 2020-10-15
US20240293355A1 (en) 2024-09-05
JP2017526693A (ja) 2017-09-14
DK3188727T3 (da) 2023-02-06
US20200237712A1 (en) 2020-07-30
CA2957588A1 (en) 2016-03-10
US20220133681A1 (en) 2022-05-05
US10653665B2 (en) 2020-05-19
AU2015312252B2 (en) 2020-07-02
CA3124872A1 (en) 2016-03-10
KR20240015729A (ko) 2024-02-05
WO2016036619A1 (en) 2016-03-10
HUE061051T2 (hu) 2023-05-28
CN106604726A (zh) 2017-04-26
MX386150B (es) 2025-03-18
AU2020239640B2 (en) 2020-11-05
JP7132277B2 (ja) 2022-09-06
CA2957588C (en) 2021-08-31
BR112017003644A2 (pt) 2017-11-28
PT3188727T (pt) 2023-01-30
US10179119B2 (en) 2019-01-15
NZ765911A (en) 2023-08-25
FI3188727T3 (fi) 2023-02-20
HRP20230070T1 (hr) 2023-03-17
JP2020143159A (ja) 2020-09-10
US11266622B2 (en) 2022-03-08
MX2017002796A (es) 2017-06-09
AU2015312252A1 (en) 2017-03-30
EP3188727A1 (en) 2017-07-12

Similar Documents

Publication Publication Date Title
AU2020239640B2 (en) Tasimelteon for treating smith-magenis syndrome
Yukuhiro et al. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys
Segarra et al. Congenital ataxia and hemiplegic migraine with cerebral edema associated with a novel gain of function mutation in the calcium channel CACNA1A
EA015256B1 (ru) Производные тетрагидроизохинолина для повышения функции памяти
JP2018520189A (ja) ガボキサドールでの発達障害の処置方法
EP3920898B1 (en) Methods and compositions for treating sleep apnea
CN104519877A (zh) 昼夜节律紊乱的治疗
US20140163050A1 (en) Use of 1H-quinazoline-2,4-diones
KR20010072184A (ko) 난치성 간질 치료약 또는 예방약
NZ729901B2 (en) Tasimelteon for treating smith-magenis syndrome
AU2011376333A1 (en) Use of 1H-quinazoline- 2, 4 -diones for use in the prevention or treatment photosensitive epilepsy
NZ765911B2 (en) Tasimelteon for treating smith-magenis syndrome
KR20100055428A (ko) 수면 장애의 치료
BR122024024457A2 (pt) Usos e composições para tratamento da apneia do sono e kit relacionado

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2024101000162; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20240122

Effective date: 20241128

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20241128

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2017 7009052

Appeal request date: 20240122

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2024101000162